Torrance Clinical Research Institute, Inc. | Lomita, CA
Status and phase
Conditions
Treatments
About
The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.
Full description
This is a phase 1b/2a, open label study to assess the safety, PK, and efficacy of IMG-007 in adult AA participants with 50% or greater scalp hair loss. The study will consist of two cohorts with three periods: a screening period of up to 5 -weeks, a 16-week treatment period and a 20-week follow- up period. Approximately 6 and 24 participants will be sequentially enrolled into cohort 1 and cohort 2, respectively, to receive three intravenous infusions of IMG-007 over 4 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
30 participants in 2 patient groups
Loading...
Central trial contact
Duong Nguyen
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal